Outcome of Patients Receiving Thrombolytic Therapy V Nonvalvular Atrial Fibrillation (From Rivaroxaban Once Inhibition Compared With Vitamin K Antagonism for P Trial in Atrial Fibrillation)

American Journal of Cardiology

120, 1837-1840

DOI: 10.1016/j.amjcard.2017.07.095

Citation Report

#	Article	IF	Citations
1	Thrombolytics/Warfarin. Reactions Weekly, 2017, 1679, 198.	0.0	0
2	Factor Xa Inhibition and sPESI Failure in Intermediate-High-Risk Pulmonary Embolism. American Journal of Emergency Medicine, 2018, 36, 1925.e3-1925.e4.	2.5	2
3	Assessing Patient Preferences for Switching From Warfarin to Direct Oral Anticoagulants. Journal of Thrombosis and Thrombolysis, 2019, 48, 596-602.	2.2	19
4	Clinical Presentation, Diagnostic Findings and Management of Cerebral Ischemic Events in Patients on Treatment With Non-Vitamin K Antagonist Oral Anticoagulants – A Systematic Review. PLoS ONE, 2019, 14, e0213379.	3.2	21
5	Comparative Effectiveness and Safety of Rivaroxaban in Adults With Nonvalvular Atrial Fibrillation. American Journal of Therapeutics, 2019, 26, e679.	1.1	4
6	Safety of Intravenous Thrombolysis Among Patients Taking Direct Oral Anticoagulants. Stroke, 2020, 51, 533-541.	9.1	80
7	Complex Clinical Scenarios With the Use of Direct Oral Anticoagulants in Patients With Atrial Fibrillation: A Multidisciplinary Expert Advisory Board. Netherlands Heart Journal, 2020, 28, 504-513.	2.6	2
8	Ischaemic Stroke in Anticoagulated Patients With Atrial Fibrillation. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 1164-1172.	7.1	37
9	Treatment With Edoxaban Attenuates Acute Stroke Severity in Mice by Reducing Blood–Brain Barrier Damage and Inflammation. International Journal of Molecular Sciences, 2021, 22, 9893.	5.9	12
10	Urticaria vasculitis secundaria al uso de inhibidores directos del factor Xa. REC: CardioClinics, 2019, 54, 129-130.	0.3	0
11	Intravenous Thrombolysis for Patients With Acute Ischemic Stroke While Receiving a Direct Oral Anticoagulant: A Systematic Review and Meta-Analysis. Pharmacotherapy, 2025, 45, 111-123.	4.3	3